Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
adalimumab, Aileron, Albireo, AMAG, AMT, anthony, azathioprine, Biogen, brain, cap, carryback, carryforward, context, customer, disability, Domain, dual, Dunedin, earliest, enabling, forward, Fosun, grantee, Greenhill, indefinitely, infliximab, Integra, IRC, Israeli, licensee, Macau, mainland, manning, median, MediWound, mercaptopurine, mesalazine, methotrexate, mild, modification, Momenta, neurodegenerative, Otago, Pharmacia, piece, prednisone, preparatory, prohormone, proportional, PSL, repeal, repealed, restated, reversal, Roche, SARL, Shanghai, stapled, Taiwan, translational, tumor, undelivered, underwriting, unutilized, vendor, Willow
Removed:
achieved, admission, adrenergic, airway, albuterol, alprostadil, amortize, anticholinergic, approaching, arm, arrest, ascending, attributed, baseline, behavior, biochemical, blinded, bronchodilator, bupropion, buspirone, cachexia, Caverject, degradation, dermatologic, discontinuation, eating, emergency, endopeptidase, energy, enrolled, erectile, excrete, exploring, facial, feeling, flushing, FSFI, functioning, guinea, heliox, helium, hormonal, hydrochloride, imaging, Impulse, inhalation, inhaled, injected, intake, intensively, International, intubation, ipratropium, Levitra, mechanical, metabolize, mixture, multicenter, MUSE, nebulized, negotiate, negotiating, neutral, oxygen, parallel, past, patch, penile, pig, pooled, potent, preferable, questionnaire, refractory, relax, repeat, resistant, safely, satiety, score, selection, sensitized, sildenafil, slowly, suppository, surgical, surgically, symptom, syndrome, tadalafil, tolerability, transdermal, trazodone, Union, unremitting, unresponsive, urethral, utilization, vacuum, vardenafil, vascular, ventilation, Viagra, wasting, weight
Filing tables
Filing exhibits
- 10-K Annual report
- 23 Consents of Experts and Counsel
- 31.1 Certification Pursuant to Rule 13A-14(A)/15D-14(A) Certifications Section 302 of the Sarbanes-oxly Act of 2002
- 31.2 Certification Pursuant to Rule 13A-14(A)/15D-14(A) Certifications Section 302 of the Sarbanes-oxly Act of 2002
- 32.1 Certificate Pursuant to Section 18 U.s.c. Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 32.2 Certificate Pursuant to Section 18 U.s.c. Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- Download Excel data file
- View Excel data file
Related press release
PTN similar filings
Filing view
External links
EXHIBIT 23
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Palatin Technologies, Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-33569, 333-56605, 333-64951, 333-72873, 333-84421, 333-52024, 333-54918, 333-74990, 333-100469, 333-101764, 333-104370, 333-112908, 333-128585, 333-132369, 333-140648, 333-146392, 333-174251, 333-183837, 333-185113, 333-201821, 333-206003, and 333-206047) on Form S-3 and in the registration statements (Nos. 333-57079, 333-83876, 333-128854, 333-149093, 333-163158, 333-174257, 333-191467, 333-206009 and 333-214618) on Form S-8 of Palatin Technologies, Inc. of our report dated September 25, 2017, with respect to the consolidated balance sheets of Palatin Technologies, Inc. and subsidiary as of June 30, 2017 and 2016, and the related consolidated statements of operations, comprehensive loss, stockholders’ (deficiency) equity, and cash flows for each of the years in the three-year period ended June 30, 2017, which report appears in the June 30, 2017 annual report on Form 10-K of Palatin Technologies, Inc.
Philadelphia, Pennsylvania
September 25, 2017